My Treatment Approach: Optimizing Care for Patients with Polycythemia Vera

Dr. Pankit Vachhani from the University of Alabama at Birmingham and Dr. Firas El Chaer from Miami Cancer Institute discussed key considerations in managing polycythemia vera (PV), including thrombotic risk assessment and treatment decision-making across the disease course. The discussion emphasized moving beyond traditional binary risk stratification (age >60 years, prior thrombosis) to comprehensive assessment incorporating white blood cell count control, symptom burden, and disease-modifying therapy selection. Two real-world patient scenarios illustrated evolving management approaches: a 54-year-old initially low-risk patient requiring frequent phlebotomies despite hydroxyurea, and a 68-year-old with progressive splenomegaly and rising white blood cell counts despite hematocrit control. Both cases demonstrated hydroxyurea resistance/intolerance requiring treatment escalation. Clinical Considerations: Frequent phlebotomies (>3 annually) indicate cytoreductive therapy failure requiring reassessment White blood cell count >11,000 represents independent thrombotic risk factor necessitating treatment optimization Symptom burden assessment using MPN10/MPNSAF tools guides therapy decisions ROPEG interferon alfa-2b and ruxolitinib offer event-free survival advantages as second-line therapies Hematocrit <45% represents minimum control standard, not comprehensive disease management goal